Leaders in Pre Formulation and Formulation to Meet This April

LONDON, February 23, 2011 /PRNewswire/ -- Senior leaders from across the industry will meet at Pharma IQ's Global Pre Formulation and Formulation Summit in Amsterdam this April to discuss latest developments and challenges in the field.

With the cost of discovering and developing a new drug predicted to tip at approximately $900 million, the pressure to reduce time/costs to market while ensuring soluble, stable and profitable products is higher than ever.

To tackle this issue, many pharmaceutical companies are now more than ever streamlining their development strategies and implementing predictive approaches to mitigate risk and ensure investment in successful candidates.

Pharma IQ's Pre Formulation and Formulation Summit 2011 will bring together senior level experts to share case studies, insights and best practice strategies to help:

    - Accelerate early development and pre-formulation through
      implementation of an efficient streamlined approach to reduce time and
      cost to market

    - Mitigate risks in later development through inter
      departmental integration to avoid late stage drug attrition and
      maximise profitability

    - Capitalise on outsourcing partnerships in western and
      emerging markets through critical business analysis of when, where and
      how to outsource

    - Tailor development approaches to enable accurate and
      efficient formulation of paediatric drugs to ensure first time
      regulatory acceptance

    - Enhance drug solubility and dissolution through employment
      of the most cutting edge approaches to ensure development of stable and
      soluble formulations

Summit attendees will hear best practices from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Johnson and Johnson, Lundbeck, Merck, Neurosearch and many many more.

Pharma IQ's Global Pre Formulation and Formulation Summit 2011 will be held from the 11th - 13th April in Amsterdam. For more information about the conference and to access exclusive and complimentary industry resources, please visit http://www.pharmaceuticalpreformulation.com/leaders or phone +44(0)207-368-9300.

SOURCE Pharma IQ

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.